Phaseline

Companies › Innovent Biologics (Suzhou)

Innovent Biologics (Suzhou): clinical trials, targets and expected readouts

28 active drug programs in 68 registered trials: 29 Phase 1, 18 Phase 2, 16 Phase 3, 5 Phase 4; Oncology, Other, Metabolic and endocrine, Ophthalmology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Teprotumumab (N01)
Insulin-like growth factor I receptor antagonist
IGF1RPhase 4Thyroid Eye DiseaseJun 2028
IBI363
Mutated IL-2 cytokine fused to anti-PD-1 antibody; combines IL-2 pathway stimulation with
PDCD1, IL2Phase 3Colorectal Cancer; Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer; Melanoma; Solid Tumors or Lymphoma …Nov 2026
IBI343
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Cancer; CLDN18.2 Positive; Locally Advanced Unresectable or Metastatic Solid Tumors …Dec 2026
IBI311
IGF-1 receptor antagonist
IGF1RPhase 3Thyroid Eye Disease; Thyroid Associated OphthalmopathiesDec 2026
IBI362
GLP-1 receptor agonist
GLP1RPhase 3Overweight; Sleep Apnea; Adolescents With Obesity or Overweight With Weight-Related Comorbidities; Obesity …Dec 2026
IBI302
Anti-VEGF monoclonal antibody
VEGFAPhase 3Neovascular Age-related Macular DegenerationFeb 2027
Tafolecimab (IBI306)
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 3Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia; Acute Coronary Syndrome; Lung Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC) …Feb 2027
IBI3003
Trispecific antibody
–Phase 3Relapsed or Refractory Multiple Myeloma; Multiple MyelomaOct 2027
IBI354
HER2-directed antibody-drug conjugate
ERBB2Phase 3Ovarian; Locally Advanced Unresectable or Metastatic Solid TumorsDec 2027
IBI310
CTLA-4 inhibitor
CTLA4Phase 3MSI-HApr 2028
Sintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3MSI-HApr 2028
IBI3027
IL-4 receptor alpha antagonist (anti-IL-4Rα antibody)
IL4RPhase 3Atopic Dermatitis; Healthy VolunteersJul 2028
Sindilizumab
PD-1 inhibitor
PDCD1Phase 3Non-Small Cell Lung Cancer; SBRT; Colorectal Cancer Metastatic; Hepatoid Adenocarcinoma of StomachOct 2028
IBI3016–Phase 2HypertensionJan 2027
IBI3002
IL-4Rα inhibitor
–Phase 2Atopic Dermatitis; AsthmaMar 2027
IBI356
Bispecific antibody targeting IL-4 receptor alpha and OX40
–Phase 2Atopic Dermatitis–
IBI3033–Phase 1Healthy ParticipantsNov 2026
IBI3031–Phase 1Thyroid Eye DiseaseJun 2027
IBI3005
Bispecific monoclonal antibody-camptothecin derivative conjugate
–Phase 1UnresectableJun 2027
IBI3014–Phase 1Unresectable Locally Advanced or Metastatic Solid TumorsJun 2027
IBI3035
Long-acting basal insulin analog
–Phase 1Healthy PersonJul 2027
IBI351
KRAS G12C inhibitor
KRASPhase 1Advanced Non-Small Cell Lung CancerJul 2027
IBI3009
Monoclonal antibody-camptothecin derivative conjugate
–Phase 1Small Cell Lung CancerAug 2027
IBI3042
GLP-1 receptor agonist
–Phase 1OverweightSep 2027
IBI3013
Recombinant anti-IL-15 monoclonal antibody
IL15Phase 1HealthyDec 2027
IBI115–Phase 1Small Cell Lung Cancer (SCLC)Feb 2028
IBI3046–Phase 1Obesity and OverweightJul 2028
IBI3011
Anti-IL-RAP humanised monoclonal antibody
IL6RPhase 1Acute Gout Flare–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05636215IBI354Phase 1Locally Advanced Unresectable or Metastatic Solid TumorsOncologyApr 2025
NCT07015762IBI3002Phase 1Atopic DermatitisImmunologyMay 2026
NCT07015749IBI3002Phase 1AsthmaRespiratoryMay 2026
NCT07295496IBI3011Phase 1Acute Gout FlareMetabolic and endocrineJun 2026
NCT07311226IBI3033Phase 1Healthy ParticipantsOtherJun 2026
NCT07502534IBI3027Phase 1Healthy VolunteersOtherJul 2026
NCT07330934IBI356Phase 2Atopic DermatitisImmunologyAug 2026
NCT07456839IBI3033Phase 1Healthy ParticipantsOtherNov 2026
NCT07122687IBI363Phase 2Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerOncologyNov 2026
NCT06081907IBI363Phase 1Advanced Solid TumorOncologyDec 2026
NCT06081907IBI363Phase 1Advanced Solid TumorOncologyDec 2026
NCT06219980SindilizumabPhase 2SBRTOncologyDec 2026
NCT06238843IBI343Phase 3Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaOncologyDec 2026
NCT06281678IBI363Phase 2MelanomaOncologyDec 2026
NCT06797297IBI363Phase 2MelanomaOncologyDec 2026
NCT05460767IBI363Phase 1Solid Tumors or LymphomaOncologyDec 2026
NCT05290597IBI363Phase 1Solid Malignancies or LymphomasOncologyDec 2026
NCT06468098IBI363Phase 1Advanced MalignanciesOncologyDec 2026
NCT06610799IBI363Phase 1IBI363 + ChemotherapyOtherDec 2026
NCT06884293IBI362Phase 3OverweightMetabolic and endocrineDec 2026
NCT07113262IBI311Phase 3Thyroid Eye DiseaseOphthalmologyDec 2026
NCT06764680SindilizumabPhase 2Colorectal Cancer MetastaticOncologyDec 2026
NCT06992362SindilizumabPhase 2Hepatoid Adenocarcinoma of StomachOncologyDec 2026
NCT06770439IBI343Phase 2Advanced Pancreatic CancersOncologyJan 2027
NCT07838220IBI3016Phase 1HypertensionCardiovascularJan 2027
NCT06862908IBI362Phase 2ObesityCardiovascularFeb 2027
NCT05972473IBI302Phase 3Neovascular Age-related Macular DegenerationOphthalmologyFeb 2027
NCT07473960Tafolecimab (IBI306)Phase 3Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaMetabolic and endocrineFeb 2027
NCT07399067IBI3002Phase 2Atopic DermatitisImmunologyMar 2027
NCT07469800IBI362Phase 3OverweightMetabolic and endocrineApr 2027
NCT07152340IBI311Phase 4Thyroid Associated OphthalmopathiesOphthalmologyApr 2027
NCT06931028IBI362Phase 3Sleep ApneaRespiratoryMay 2027
NCT07000955IBI362Phase 1ObesityMetabolic and endocrineMay 2027
NCT06421298Tafolecimab (IBI306)Phase 2Lung CancerOncologyMay 2027
NCT07152366IBI311Phase 4Thyroid Associated OphthalmopathiesOphthalmologyMay 2027
NCT07622368IBI3031Phase 1Thyroid Eye DiseaseOphthalmologyJun 2027
NCT07066098IBI343Phase 3Pancreatic CancerOncologyJun 2027
NCT05458219IBI343Phase 1Locally Advanced Unresectable or Metastatic Solid TumorsOncologyJun 2027
NCT06418061IBI3005Phase 1UnresectableOncologyJun 2027
NCT06974812IBI3014Phase 1Unresectable Locally Advanced or Metastatic Solid TumorsOncologyJun 2027
NCT07152392IBI311Phase 4Thyroid Associated OphthalmopathiesOphthalmologyJul 2027
NCT07025889IBI343Phase 1Gastric CancerOncologyJul 2027
NCT06937749IBI362Phase 2Metabolic Dysfunction-associated Steatohepatitis (MASH)Metabolic and endocrineJul 2027
NCT07591519IBI3035Phase 1Healthy PersonOtherJul 2027
NCT05504278IBI351Phase 1Advanced Non-Small Cell Lung CancerOncologyJul 2027
NCT07061535Tafolecimab (IBI306)Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)OncologyAug 2027
NCT06613009IBI3009Phase 1Small Cell Lung CancerOncologyAug 2027
NCT07793019IBI3042Phase 1OverweightMetabolic and endocrineSep 2027
NCT07556796IBI3016Phase 1HypertensionCardiovascularOct 2027
NCT07255209IBI362Phase 3Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesMetabolic and endocrineOct 2027
NCT06083207IBI3003Phase 1Multiple MyelomaOncologyOct 2027
NCT06834672IBI354Phase 3OvarianOncologyDec 2027
NCT07554222IBI3013Phase 1HealthyImmunologyDec 2027
NCT07559019IBI115Phase 1Small Cell Lung Cancer (SCLC)OncologyFeb 2028
NCT06096909Tafolecimab (IBI306)Phase 4Acute Coronary SyndromeCardiovascularMar 2028
NCT07483554IBI343Phase 2CLDN18.2 PositiveGastroenterologyMar 2028
NCT05890742IBI310Phase 3MSI-HOtherApr 2028
NCT05890742SintilimabPhase 3MSI-HOtherApr 2028
NCT07265258Teprotumumab (N01)Phase 4Thyroid Eye DiseaseOphthalmologyJun 2028
NCT07754786IBI3027Phase 3Atopic DermatitisImmunologyJul 2028

The 60 nearest readouts of 68 trials; the rest in the app.

Targets

PDCD1 (3) IGF1R (2) IL2 (1) GLP1R (1) CLDN18 (1) IL6R (1) KRAS (1) ERBB2 (1) CTLA4 (1) VEGFA (1) PCSK9 (1) IL4R (1)

Companies with the same targets

AstraZeneca Eli Lilly Roche Akeso Novo Nordisk Regeneron Pharmaceuticals Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Johnson & Johnson (Janssen) Shenyang Sunshine Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.